Physician profile
David J Kim
NPI 1730170804
$118,964.58
in general payments reported to CMS, 2019-2025
42 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $15K · 2021: $19K · 2022: $8,411 · 2023: $2,113 · 2024: $6,596 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $8,679 · Consulting Fee: $7,820 · Travel and Lodging: $482 · Education: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,473.00 |
| Food and Beverage | $8,678.77 |
| Consulting Fee | $7,820.00 |
| Travel and Lodging | $482.16 |
| Education | $481.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $65,364.86 | 2019-2025 | Livdelzi |
| Ipsen Biopharmaceuticals, INC | $17,987.70 | 2024-2025 | Iqirvo |
| Abbvie INC. | $17,927.27 | 2019-2025 | |
| Madrigal Pharmaceuticals | $7,077.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,107.07 | 2019-2025 | Xifaxan, Plenvu |
| Intercept Pharmaceuticals, INC. | $1,992.27 | 2019-2025 | Ocaliva |
| Janssen Biotech, INC. | $1,365.17 | 2020-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,251.47 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $313.48 | 2019-2025 | |
| Lilly USA, LLC | $206.63 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $201.32 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $195.87 | 2024-2025 | Dupixent |
| Astellas Pharma US INC | $170.98 | 2025 | |
| Celgene Corporation | $154.94 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $150.92 | 2024-2025 | Voquezna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $147.95 | 2025 | Terlivaz |
| Echosens North America, INC. | $139.53 | 2023 | Fibroscan |
| Celltrion USA INC. | $129.43 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $116.85 | 2021-2025 | Suflave, Sutab |
| Ardelyx, INC. | $107.45 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $104.10 | 2022-2024 | |
| Vivus LLC | $68.57 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.45 | 2019-2024 | Dificid |
| Genzyme Corporation | $59.59 | 2022-2023 | |
| Amgen INC. | $54.21 | 2021 | |
| Exact Sciences Corporation | $50.36 | 2023-2024 | Cologuard Collection Kit |
| Shire North American Group INC | $47.82 | 2019 | |
| Novo Nordisk INC | $47.73 | 2025 | |
| W. L. Gore & Associates, INC. | $39.02 | 2022 | |
| Mirum Pharmaceuticals, INC. | $38.88 | 2024-2025 | Livmarli |
| Nestle Healthcare Nutrition INC. | $37.31 | 2021 | |
| Ucb, INC. | $31.39 | 2019 | |
| Alexion Pharmaceuticals, INC. | $31.35 | 2019-2023 | Strensiq |
| Evoke Pharma, INC. | $28.86 | 2022 | |
| Daiichi Sankyo INC. | $25.31 | 2022 | |
| Sandoz INC. | $23.65 | 2023 | Hyrimoz |
| Glaxosmithkline, LLC. | $22.80 | 2025 | |
| Romark Laboratories, Lc | $22.73 | 2020 | |
| Organon LLC | $21.57 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.70 | 2023 | Rebyota |
| Dova Pharmaceuticals | $14.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$57,250.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.